AFMD News and Press, Affimed N.V. From 05/24/22

HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release ...

Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapies First preclinical data set on the combination of AFM28 with natural killer cells, both in co-administration or pre-complexed, demonstrates cytoto...

The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity. AFM28 induces effective lysis of hematological tumor cells even at low-levels of CD123 expression; leukemic cells in patient bone marr...

A lot of small biotechs are fantastic buys right now. With Big Pharma sitting on a lot of cash, we might start seeing some smart acquisitions later this year. We asked a trio of contributors to pick the biotechs they're feeling most bullish about as potential buyout candidates in 2022. ...

HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the American Soc...

In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American Society of Clinical Oncology (ASCO), not the American Association for Cancer Research. The corre...

A presentation on the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13, in patients with CD30-positive lymphomas will be given in an oral abstract session. Three Trial in Progress posters will present background infor...

The following slide deck was published by Affimed N.V. in conjunction with this event. For further details see: Affimed (AFMD) Investor Presentation - Slideshow

German biotech Affimed (NASDAQ:AFMD) has priced its previously announced public offering of 22.5M of its common shares at a public offering price of $4.00/common share for expected net proceeds of $84.6M. Underwriters green shoe options is for another 3,375,000 common shares. O...

HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its p...